Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

The price of Coherus Biosciences Inc (NASDAQ: CHRS) closed at $1.15 in the last session, up 7.48% from day before closing price of $1.07. In other words, the price has increased by $7.48 from its previous closing price. On the day, 1.46 million shares were traded.

Ratios:

We take a closer look at CHRS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.09 and its Current Ratio is at 1.25.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.

On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.44.

Stock Price History:

Over the past 52 weeks, CHRS has reached a high of $2.65, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -15.05%, while the 200-Day Moving Average is calculated to be -15.84%.

Shares Statistics:

A total of 115.21M shares are outstanding, with a floating share count of 111.28M. Insiders hold about 3.97% of the company’s shares, while institutions hold 55.44% stake in the company.

Most Popular